Breaking News

FDA weighs in on orphan drug exclusivity; PhRMA terminates lobbying contract with White House official's brother

January 23, 2023
Pharmalot Columnist, Senior Writer
Andrew Harnik/AP

STAT+ | Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity

The FDA's approach had come under question amid a battle betwenen rare disease drugmakers Jacobus and Catalyst.

By Ed Silverman


STAT+ | PhRMA terminates lobbying contract with White House official's brother

PhRMA has terminated its contract with Jeff Ricchetti, a lobbyist who is the brother of a prominent Biden White House official.

By Rachel Cohrs


STAT+ | Pliant claims early success in hard-to-treat progressive lung disease

Pliant says an experimental pill significantly improved lung function in patients with IPF, a deadly disease with few approved treatments.

By Jason Mast



Mario Tama/Getty

FDA scientists propose an annual Covid shot matched to current strains

The new proposals were outlined ahead of a meeting of the FDA's advisory panel on vaccines and related biological products.

By Matthew Herper


STAT+ | How one private biotech seized on JPM to emerge from stealth and tell its story

The team behind Rezo Therapeutics spent weeks honing a pitch deck to appeal to attendees and explain what, exactly, they had been up to.

By Allison DeAngelis


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments